Fullerene C60 activates tumor immunity by polarizing tumor-associated macrophages and combines with immune checkpoint inhibitors (PD-L1 monoclonal antibody) to achieve efficient tumor immunotherapy [19]. This evidence concerns the gene CD274 and neoplasm.